SELECTA BIOSCIENCES, INC. (NASDAQ:SELB) Files An 8-K Regulation FD Disclosure

SELECTA BIOSCIENCES, INC. (NASDAQ:SELB) Files An 8-K Regulation FD Disclosure

Story continues below

Item 7.01. Regulation FD Disclosure.

Selecta Biosciences, Inc. (the Company) from time to time
presents and/or distributes to the investment community at
various industry and other conferences slide presentations to
provide updates and summaries of its business. A copy of its
current corporate slide presentation is attached to this Current
Report on Form 8-K as Exhibit 99.1. The Company undertakes no
obligation to update, supplement or amend the materials attached
hereto as Exhibit 99.1.
The information in Item 7.01 of this Form 8-K, including Exhibit
99.1 attached hereto, shall not be deemed filed for purposes of
Section 18 of the Securities Exchange Act of 1934, as amended
(the Exchange Act) or otherwise subject to the liabilities of
that section, nor shall it be deemed incorporated by reference in
any filing under the Securities Act of 1933, as amended, or the
Exchange Act, except as expressly set forth by specific reference
in such a filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
Corporate slide presentation of Selecta Biosciences,
Inc. dated January 2017


Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company using its synthetic vaccine particle (SVP) technology to discover and develop targeted therapies that are designed to modulate the immune system to treat rare and serious diseases. The Company is engaged in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The Company’s product candidates are in development. The Company’s SVP technology encapsulates an immunomodulator in biodegradable nanoparticles to induce antigen-specific immune tolerance to mitigate the formation of anti-drug antibodies (ADAs) in response to life-sustaining biologic drugs. The Company’s technology allows for the design of SVP therapies that can stimulate immune responses against a range of relevant antigens. Its initial immune-stimulating product candidate is a synthetic vaccine against nicotine for the market of smoking cessation and relapse prevention.


SELECTA BIOSCIENCES, INC. (NASDAQ:SELB) closed its last trading session up +0.48 at 16.87 with 28,734 shares trading hands.

An ad to help with our costs